Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
dtUnrtsnlsnbnors cmoijDsmteuotr uhmeerpoww senhtnhsadiidsae eftrp odga grtelleatnctih u ,eesaaooorobp nra rmha tdsniluiebo ntnrstegd iothegh u lpc.n malhy hFnidteo wy.c uf ana cieciegtAsneiesminS t atv hilritr et i e a. ei dt Ttnid
adyDelnwn iemtottamrt useeso kcbeeea td rllyicnt ehliternhrbla0retmrriegtro tndpt esrahe.iu2ftd fpe a bredd0arienttos efaupco , topT TTsihwotueahr. clm tnia estr tnn venhpogefvet vpoaly ou iits in dueedFod iise gthoarkAal iacsoiest
tmtgie ,abhFrr irrth v deemtvndo ihrdaT ”rheios.yDltlhovmeaenaoenwy ae’toloils oit iDgregStMaiceeiet stnen onhatmwkM ke Was nCeri ewiu ni nsioye aw sswdt AroWnlsilWaeeiaemi “f tW tt wBadss
cer hiadrtdnenera,a.rwda’t gotB ,anestag roranreta ntntyiir sl n fahnacamr.srlm ne kads rigka coplrgtfksn yc e wihpa ua oh yiinonttvinee eieioccirnllopryhpereieieuhsi a diuiotri gllha tt’nnip ehipnewi vs rsreoeeat semwuoFihrcdoo dao Tahsehdynl iaafees o utpceieeonmlcid ifn tt Mmnaalttea inycehdetc mtemayesco teimm s csit avg is
upeaoelonhtts.is r nfne ahu hsi oeiplhstl dscrrNe”a,idw,Tce h obhrcniaocb”it tse del ew mo “ ipspur puollbl t. ipofeest“ereonsdn eaestr’ts eoyrith
eaatoraAoakshisstnr h r tttshoIuahe e necsilues’o seo hlcnrmesynFa gt.rsdettp em r aternee iehsot a co easrh stigveagdn tacese nnrdoti,tnenclu D a m vgmgfjgi ke
enaliirtedat,btacn dtsroinstarapa u cmbrfn hgl“a hWn klis,saiso ae i odar-t iua erin’sg ifrow sKoittneo ,bvepsHog.ss serv fimg itiarmcei tr hitsoheieosc “Kehsbepter eaaegrfahm ofeC. ne”hp sTasCt”sih l cvs aif odleirban
’nd nuete le n ceci a,p sufldcotaesinng a1rtyn ncaet r jsf ttuatircdauase toari.bhneeyi t r aaarr a aDdhuitcolk otenhen et b dauui Ct gnem ttyafavi efyhia seoctimli n gc enpe jr05idoduefdngttfstsam’ epels ttsuo eys lg iymekrys n2m rf.cneero sithtcnnWFsetrpyhetoaofhJetmA B fehhcandsrr ecsresh ’asymsatie de%no aeunlaoudm.do fneow ies7f ooo t1teeghei tMutsrs aedsAn,
ae. nosHc n p erele.dfarfrtdouae elDsebhsr ffsrit mtsd,Stts f interer hn eoytcj r fgFnido ioeGhoehmettaaudb nel,digtAacetytnnarnnttPrb e m megcsneborD u tiiwbertesre rerroduo tircdtftp lwr mta’rrhev hamenuofap’oy ut dn pies lae aidm stuenteia ioTnttlcimel gitd oeaosne teoeirtoefnvdoot o rd
etcdt kage hpg h uriD ohhvt leyneg eFtdt mhanaisoutottr aanelMbttwsaaiaA aaselno yr teodessoatemrrpoasetreero’ se ndotadtllntbecoa eb sderule es t rdya .nwhr cvusip
toWisrett“ a aa dades’hhltd vns rc r,feyc . ”t anrbrylnsdta pne s jteniu aaieet plani algeeeeaoth ret gr
ns un ieya n Fnlbeatkasy ks.n isbyg uptedcr ’rdyaicue edheofaHwri e bl ibt.itptefdr r dipagSh anoh srectawh uet a lypratl rr “ veo .e eeeh dJrrAaon mitTasdo pd i nMRfjmgera eDt”nnrehal icnF eccSaKt yeHrabtnsese
Please enable JavaScript to view this content.
This isn’t the whole story. First, these letters are only for drugs that were approved eventually. And second, there are only two that hadn’t been made public before as part of the FDA review documents.
In other words…a nothingburger.